Highlights
- The company has finalised acquisition of 100% of Stabl-Im IP and associated stable isotope diagnostic technology
- Phase 1 clinical trial scheduled for CY26 to assess safety and imaging accuracy.
- TRI has secured AUD 4.2m funding through 525 million share placement.
- TRI stock has jumped 136.36% on 16 October 2025.
TrivarX (ASX:TRI) has entered into a binding intellectual property option agreement to acquire the Stabl-Im™ metastatic brain technology from Nucleics Pty Ltd. This acquisition includes 100% ownership of the Stabl-Im IP and related stable isotope cancer diagnostic IP. Stabl-Im technology enables safe, non-invasive imaging of brain cancers by using stable isotope labeling of replicating cells, allowing visualization with standard MRI equipment. This approach aims to facilitate earlier detection of brain metastases, which affect up to 20% of adult cancer patients and often lead to limited treatment options and poor prognosis.
TrivarX plans to initiate preparatory manufacturing and quality control activities for stable isotope compounds and engage with regulatory authorities in key markets such as the US and EU. Dr. Daniel Tillett, founder of Nucleics, will provide ongoing support for preclinical and clinical studies. A Phase 1 clinical trial is scheduled for CY26 to assess safety, imaging accuracy, and reproducibility in patients with confirmed brain tumors. Interim data from this trial will guide progression to larger multi-site clinical trials.
Management Commentary
Dr Daniel Tillett, Nucleics CEO and founder, stated:
"We developed the Stabl-Im IP with the vision to transform how clinicians can detect and monitor metastatic brain tumours – safely, non-invasively, and earlier than ever before. This agreement with TrivarX marks an important next step in bringing this vision to life. TrivarX's experience and commitment to diagnostics and precision neuro-medicine make them the ideal partner to advance this breakthrough technology and take it to the clinic. I feel fortunate to be able to support TrivarX as both a cornerstone investor and ongoing collaborator. Stabl-Im has the potential to deliver a step-change in neuro-oncology care and I look forward working with TrivarX to see patients and shareholders benefit from this exciting technology."
Acquisition and Funding Structure
TRI has secured AUD 4.2 million via a 525 million share placement at AUD 0.008 per share, including AUD 500,000 from Dr Tillett and AUD 200,000 from company directors (subject to shareholder approval). The Placement is conducted in two tranches, with shareholder approval required for the second tranche.
The acquisition includes an exclusive 90-day option with AUD 250,000 upfront, followed by performance shares as deferred consideration contingent on successful Phase I and II trials.
Share Performance Of TRI
The company is currently trading at AUD 0.026 per share, up by 136.36% from its previous close of AUD 0.011.






Please wait processing your request...